Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.52 |
| ▸ | ALB | P02768 | 3/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910840 | 1.00 | LMNA (0.52) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL21239415 | 1.00 | LMNA (0.52) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL1628462 | 1.00 | LMNA (0.52) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL22810381 | 0.80 | CHRNB2 (0.40) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL21507259 | 0.78 | DNMT1 (0.49) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL21239414 | 0.78 | DNMT1 (0.49) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL25790547 | 0.78 | DNMT1 (0.49) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12671946 | 0.78 | ABL1 (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| 4'-Thio-2'-Deoxycytidine SCHEMBL24043143 | 0.77 | LMNA (0.53) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL9530859 | 0.77 | LMNA (0.57) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6177435-B1 | DETECTING ZIDOVUDINE RESISTANCE; ADMINISTERING 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE; ALTERNATING DRUG CYCLES | GLAXO WELLCOME INC. | 2001-01-23 | — | — | US | claimed |
| EP-0639971-B1 | THERAPEUTIC COMBINATIONS | WELLCOME FOUND (GB) | 1999-09-22 | — | — | EP | claimed |
| WO-1995011685-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-05-04 | — | — | WO | claimed |
| EP-0639971-A1 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023021-A2 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-11-25 | — | — | WO | claimed |
| EP-0525106-A4 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | — | 1993-04-21 | — | — | EP | claimed |
| EP-0525106-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1993-02-03 | — | — | EP | claimed |
| EP-0506935-A1 | NOVEL RIBONUCLEOSIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAID COMPOUNDS | PASTEUR MERIEUX SERUMS ET VACCINS, Société Anonyme : (FR) | 1992-10-07 | — | — | EP | claimed |
| US-5128458-A | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-07 | — | — | US | claimed |
| WO-1992006993-A1 | NOVEL RIBONUCLEOSIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAID COMPOUNDS | PASTEUR MERIEUX SERUMS ET VACCINS (FR) | 1992-04-30 | — | — | WO | claimed |
| WO-1991016333-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-10-31 | — | — | WO | claimed |
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20050192299-A1 | Method of treating or preventing hepatitis B virus | CHENG YUNG-CHI (US) | 2005-09-01 | — | — | US | disclosed |
| EP-0639971-B1 | THERAPEUTIC COMBINATIONS | WELLCOME FOUND (GB) | 1999-09-22 | — | — | EP | disclosed |
| US-5478928-A | Useful as antiviral agents in the treatment and prevention of AIDS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-12-26 | — | — | US | disclosed |
| EP-0506935-A1 | NOVEL RIBONUCLEOSIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAID COMPOUNDS | PASTEUR MERIEUX SERUMS ET VACCINS, Société Anonyme : (FR) | 1992-10-07 | — | — | EP | disclosed |
| US-5128458-A | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-07 | — | — | US | disclosed |
| WO-1992006993-A1 | NOVEL RIBONUCLEOSIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAID COMPOUNDS | PASTEUR MERIEUX SERUMS ET VACCINS (FR) | 1992-04-30 | — | — | WO | disclosed |
| WO-1992006993-A1 | NOVEL RIBONUCLEOSIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAID COMPOUNDS | PASTEUR MERIEUX SERUMS ET VACCINS (FR) | 1992-04-30 | — | — | WO | disclosed |
| WO-1991016333-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192299-A1 | Method of treating or preventing hepatitis B virus | CDA, DCTD, TTPA | LMNA 882/4885PDE3A 1279/4885ALB 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.